Central nervous system disorders (CNS) make up more than 600 conditions that affect over 2 billion people worldwide with an estimated economic burden of more than $2 trillion in the US and EU alone. Due to this unmet medical need and financial burden, the neurotechnology sector has seen important increases in investment over the last decade. Now in its fourth year, the European Neurotech Investing and Partnering Conference is the premier partnering and investing conference for the neurotechnology industry, spanning pharmaceuticals, medical devices, software, and diagnostics for the brain and nervous system. This event will bring together C-level executives, investors, and entrepreneurs to address challenges in investing, funding, partnering, and development of new treatments and diagnostics for the brain and nervous system. Overall, this event will provide delegates with a forum to learn, network, and shape the future of their organization and the industry.



7:30 Conference Registration and Continental Breakfast

8:30 Welcome and State of the Industry Keynote
Alison Fenney, Executive Director, Neurotechnology Industry Organization

KEYNOTE PRESENTATION: From Concept to Clinic: Neurotechnology Translation Today
John Donoghue, Ph.D., Founding Director, Wyss Center

9:00 Panel Discussion: Investing in Neurotech
A diverse panel of private, public and strategic investors will discuss what it takes to get a neurotech company funded. The benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology will be addressed. Delegates will learn more about today's deal terms and valuations as well as exit strategies. Finally, the neurotech industry will be evaluated in comparison with other industries.

Moderator: John B. Reppas, M.D., Ph.D., Director of Public Policy, Neurotechnology Industry Organization

Daniel Bertholet, Senior Investment Director, Endeavour Vision
Jasper Bos, Ph.D., Vice President, Head, Healthcare Fund, Merck Ventures
Yaron Breski, MBA, Partner, RMGP Biopharma Investment Fund; Managing Director, RM Global Partners
Francesco De Rubertis, Partner, Medicxi

10:00 Coffee Break with Exhibit Viewing

10:45 Treatment for Alzheimer's and Cognitive Disorders 
Alzheimer’s disease and related dementias affect over 46 million people worldwide, with an estimated cost of $818 billion. Ongoing efforts to develop disease modifying therapies have been plagued with failures. This session will address new avenues being pursued to address the growing global need, novel diagnostics for early detection, and non-pharmacological options in development. 

Moderator: Daniel O’Connell, MBA, Founding member & Managing Partner, NeuroVentures; President and Chief Executive Officer, Acumen Pharmaceuticals, Inc.

Alzheon, Inc. – A Precision Medicine Approach to Alzheimer’s Disease

Martin Tolar, M.D., Ph.D., Founder, President & CEO, Alzheon, Inc.

O-Glcnacase Inhibitor ASN120290 as Anti-Tau Drug Candidate for Alzheimer’s Disease and Other Tauopathies

Dirk Beher, Ph.D., CEO, Asceneuron SA

ORY-2001 an Epigenetic Inhibitor Targeting LSD1 is a Therapeutic Candidate to Treat Alzheimer’s Disease and Other Neurodegenerative Disorders

Carlos Buesa, Ph.D., CEO, Oryzon

12:15 Networking Luncheon

14:15 Panel Discussion: Internal & External Research and Development

Big pharma, medtech, and biotech companies collaborate with smaller companies and academic institutions on a variety of projects. This panel discussion will address opportunities for research and development collaborations with academic groups, research institutes, and platform companies. Delegates will learn how to spot opportunities, current areas of interest, and how to focus internal and external resources.

Moderator: Carla M. Lema Tome, MBA, Ph.D., Senior Consultant, Medical and Commercial Strategy, INC Research
Pierandrea Muglia, M.D., Vice President, Head, Neuroscience Discovery Medicine, UCB Pharma
Jeff Erb, Senior Director, Strategy, Business Development and Alliance Management, Medtronic

15:15 Refreshment Break with Exhibit Viewing

16:00 Frontiers in Neurotechnology 
This session includes companies on the cutting edge of neuroscience. Novel neurostimulation devices for a variety of indications, software solutions for neuropsychiatric markets, and new neurodiagnostic tools are on the brink of success. Companies in this session will showcase their innovative next-generation products and how they are addressing unmet needs in neurotech.

Moderator: Sharon Fan, Advisor, Triomi Medical Innovations

Combining Functional Imaging with Neuromodulation

Ann Bunnenberg, Ph.D., JD, Chief Operating Officer and President, Electrical Geodesics, Inc.

How to Revolutionize Treatments for Brain Cancer and Neurologic Conditions

Frederic Sottilini, CEO, CarThera

Wearable Brain Sensing: Assisting Patients, Clinical Trials and Wellness

Nathan Intrator, Ph.D., CEO, Neurosteer

17:00 Emerging Company Showcase

This showcase allows neurotechnology companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field. Companies presenting in this session are addressing unmet medical needs, were founded no earlier than 2012, and are actively seeking funding.

Moderator: Alison Fenney, Executive Director, Neurotechnology Industry Organization

Thomas de Vlaam, CEO, Amylon Therapeutics
Haritz Zabaleta Rekondo, CTO, Fesia Technology S.L.
Efi Cohen Arazi, Director, BrainBalance
Goran Bijelic, CEO, Elcode
Jean-René Bélanger, CEO, Imeka

17:30 Welcome Reception with Exhibit Viewing

18:30 Close of Day


8:00 Conference Registration and Continental Breakfast

8:30 KEYNOTE PRESENTATION: Towards a Major Service-Based Research Infrastructure for Brain Research

Christoph Ebell, Executive Director, Human Brain Project

9:30 Coffee Break with Exhibit Viewing

10:15 Bench to Bedside, Profiling the Wyss Center Panel Discussion
This session will feature discussions around the funding and de-risking of early neurotech concepts, offer advice on how to attract investors, and give tips on how to avoid common pitfalls on the journey of a new concept from lab bench to the clinic.

Moderator: Tracy Laabs, Ph.D., Assistant Director, Wyss Center
Claude Clément, CTO, Wyss Center
Daniel O’Connell, MBA, Founding member & Managing Partner, NeuroVentures; President and Chief Executive Officer, Acumen Pharmaceuticals, Inc.
Joern Rickert, Ph.D., CEO, CorTec GmbH
Claudio Pollo, M.D., Head, Functional Neurosurgery, University Hospital Berne, Switzerland

11:15 Panel Discussion: Partnering and Licensing in Neurotech
Neurology is projected to be medtech’s fastest-growing segment in the next five years. Pharma companies are adapting to the current environment with targeted deal-making. This panel will address current trends in strategic alliances and inlicensing, priority indications and requirements for licensing deals, and companies active in deal-making.

Moderator: David A. Lowe Ph.D., Co-Founder & CEO, NeuroAssets

Maciek Drozdz, Principal, Venture Investments, J&J Development Corporation
Charlie Bailey, Ph.D., Global Head, Neuroscience, Business Development & Licensing, Novartis
Patrik Frei, Ph.D., CEO, Venture Valuation
Alexander Breidenbach, MBA, Global Head, Neuroscience Partnering, F. Hoffmann La Roche Ltd.
Catherine Abbadie, Ph.D., Senior Director, Business Development, Sunovion Pharmaceuticals Inc

12:15 Networking Luncheon

13:45 Next-Generation Psychiatry 
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a substantial portion of the neurotech market. This session will focus on the most promising next-generation treatments as well as devices and diagnostics to change the treatment landscape.

Moderator: John B. Reppas, M.D., Ph.D., Director of Public Policy, Neurotechnology Industry Organization

RP5063, a Novel Dopamine-Serotonin Stabilizer for Treating Schizophrenia and Schizoaffective Disorders

Laxminarayan Bhat, Founder, President & CEO, Reviva Pharmaceuticals Inc.

Digital Therapies for ADHD Children

Jean-Yves Quentel, CEO Mensia Technologies

14:45 Strategies in CNS Drug Development (Sponsorship opportunities available)
Intelligent trial design, fundraising, business development and product life cycle development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement.

Moderator: Anna Han, Program Lead, Industry Relations, Ontario Brain Institute

Panelists: David Ewbank, Partner, Executive Insights
Carla M. Lema Tome, MBA, Ph.D., Senior Consultant, Medical and Commercial Strategy, INC Research
Joseph Araujo, President and CEO, Intervivo

15:45 Networking Refreshment Break

16:00 Parkinson's and Other Movement Disorders
Current treatments for movement disorders can improve functioning but suffer from side effects and “off” periods especially as the disease progresses. 2017 has seen spike drug approvals in movement disorders, with strong pipelines for symptomatic treatment in development. Hear from companies developing assets and platforms to treat Parkinson’s, ALS, and orphan motor disorders.

Moderator: Alison Fenney, Executive Director, Neurotechnology Industry Organization 

Achieve Immunotherapy Candidates PD01A, PD03A Targeting Alpha Synuclein in Parkinson´s Patients

Oliver Siegel, CEO, AFFiRiS AG

Partnering in Parkinson’s Disease and Movement Disorders from Pharma’s Perspective

Atsushi Hashimoto, Director, Business Development, Mitsubishi Tanabe Holdings America, Inc.

Opening New Therapeutic Options Against Multiple Sclerosis and Other Autoimmune Diseases

Jesús Martin-Garcia, Chairman and CEO, GeNeuro

A New Drug Discovery Paradigm Pioneered by Pharnext: PLEOTHERAPYTM

Xavier Paoli, Chief Commercial Officer; VP R&D Operations, Pharnext

Selective Kinase Inhibition in the Brain

Michael Almstetter, CEO, Origenis GmbH

17:00 Close of Conference



CNPE Download Brochure




View All Sponsors